Evidence map›Paper›PMID 42426853›Full record

ArticleAlzheimer's research & therapy2026

Glycolysis-enhancing α

Qiang Zhang, Jordan L Schultz, Jacob E Simmering, Braedon Q Kirkpatrick, Matthew A Weber, Sydney Skuodas, Tara Hicks, Grace Pierce, Margaret Laughlin, Benu George and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. αPharmaceuticals (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Qiang ZhangDepartment of Neurology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, 169 Newton Road, Iowa City, IA, 52242, USA. Qiang-zhang@uiowa.edu.ORCID http://orcid.org/0000-0002-4746-0392
Jordan L SchultzDepartment of Psychiatry, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, 52242, USA.
Jacob E SimmeringDepartment of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, 52242, USA.
Braedon Q KirkpatrickDepartment of Neurology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, 169 Newton Road, Iowa City, IA, 52242, USA.
Matthew A WeberDepartment of Neurology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, 169 Newton Road, Iowa City, IA, 52242, USA.
Sydney SkuodasDepartment of Biology, University of Iowa, Iowa City, IA, 52242, USA.
Tara HicksDepartment of Biology, University of Iowa, Iowa City, IA, 52242, USA.
Grace PierceDepartment of Biology, University of Iowa, Iowa City, IA, 52242, USA.
Margaret LaughlinDepartment of Biology, University of Iowa, Iowa City, IA, 52242, USA.
Benu GeorgeDepartment of Neurology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, 169 Newton Road, Iowa City, IA, 52242, USA.
Aimee X BertolliDepartment of Neurology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, 169 Newton Road, Iowa City, IA, 52242, USA.
Travis LarsonDuke Medical Scientist Training Program, Department of Neurobiology, Duke University, Durham, NC, 27710, USA.
Ramasamy ThangavelDepartment of Neurology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, 169 Newton Road, Iowa City, IA, 52242, USA.
Mayu OyaJohns Hopkins University, Baltimore, MD, 21205, USA.
David K MeyerholzDepartment of Pathology, University of Iowa, Iowa City, IA, 52242, USA.
Georgina AldridgeDepartment of Neurology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, 169 Newton Road, Iowa City, IA, 52242, USA.
Jan FasslerDepartment of Biology, University of Iowa, Iowa City, IA, 52242, USA.
Nandakumar S NarayananDepartment of Neurology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, 169 Newton Road, Iowa City, IA, 52242, USA. Nandakumar-narayanan@uiowa.edu.

Funding

Cortical Alpha-Synuclein in DementiaR01NS129711 · NINDS · UNIVERSITY OF IOWA · PI Georgina Aldridge · 2023 to 2026
$2.3M
VTA dopamine neurons and cognitive symptoms of Parkinson’s diseaseR01NS120987 · NINDS · UNIVERSITY OF IOWA · PI NARAYANAN, NANDAKUMAR · 2021 to 2025
$2.0M
Glycolysis and Alzheimer’s DiseaseR03AG078787 · NIA · UNIVERSITY OF IOWA · PI ZHANG, QIANG · 2022 to 2023
$309k
NIA NIH HHS R03 AG078787NIH HHS R01 NS120987NIH HHS R01 NS129711NIH HHS R03 AG078787NINDS NIH HHS R01 NS120987NINDS NIH HHS R01 NS129711University of Iowa Cannon-Williams Faculty Fellowship
6 · The paper itself

Abstract

backgroundTerazosin (TZ) is widely prescribed for hypertension and benign prostatic hyperplasia. Recent studies suggest that TZ enhances glycolysis and may protect against neurodegenerative diseases.

methodsWe tested the hypothesis that TZ is neuroprotective in Alzheimer's disease (AD) in a yeast model, a mouse model, and two human datasets.

resultsWe report four main results. First, TZ increased ATP levels in a Saccharomyces cerevisiae mutant with impaired metabolism, and reduced Amyloid-beta42 (Aβ42) aggregation. Second, in 5xFAD mice, TZ attenuated amyloid pathology and rescued cognitive impairments in spatial memory and interval timing. Third, in the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, AD patients taking glycolysis-enhancing drugs had a slower progression of both cognitive dysfunction and metabolic neuroimaging biomarkers (18 F-fluorodeoxyglucose positron emission tomography (FDG-PET)). Finally, in the Merative Marketscan dataset, patients taking glycolysis-enhancing drugs had lower risks of developing AD.

conclusionThese data provide preliminary evidence that glycolysis-enhancing drugs have therapeutic potential in AD.

Indexed as

Adrenergic alpha-1 Receptor AntagonistsAlzheimer DiseaseGlycolysisPrazosinAmyloid beta-PeptidesAnimalsBrainDisease Models, AnimalHumansMaleMiceMice, TransgenicPeptide FragmentsPositron-Emission TomographySaccharomyces cerevisiaeAdrenergic alpha-1 Receptor AntagonistsAmyloid beta-Peptidesamyloid beta-protein (1-42)Peptide FragmentsPrazosinTerazosin

Identifiers

PMID42426853
PMCPMC13644072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.